Systematic evaluation of efficacy and safety of gangliosides in preventing chemotherapy-induced peripheral neurotoxicity in cancer patients
10.13699/j.cnki.1001-6821.2015.24.029
- VernacularTitle:神经节苷脂预防化疗所致周围神经毒性疗效及安全性的系统评价
- Author:
Xiao-Chen WEI
1
;
Li-Qin ZHU
;
Chun-Ge WANG
;
Qi DENG
;
Xin LI
Author Information
1. 天津市第一中心医院药学部
- Keywords:
gangliosides;
chemotherapy;
prevention;
systematic evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2015;(24):2462-2464
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the effect and safety of ganglioside -monosialic acid(GM1) in preventing chemotherapy-induced peripheral neurotoxicity ( CIPN ) in cancer patients. Methods We searched PubMed, EMbase, Cochrane, CBM, CNKI, WeiPu and WanFang Data-base from the date of establishment until April 2015.And we collected randomized controlled study that evaluated the effects of GM1 in preven-ting CIPN in cancer patients were selected.Statistical analysis was per-formed with RevMan5.3.Results Nine studies involving 770 patients were included.The results of Meta-analyses showed the following:there were statistically significant differences between GM1 group and control group in all incidence of CIPN and incidence of severe CIPN (P<0.001), while no statistically significant differences in disease con-tol rates.There was no statistically significant differences between GM1 group and Ca+Mg group in all incidence of CIPN and incidence of se-vere CIPN(P>0.05).There were statistically significant differences be-tween GM1 group and glutathione( GSH) group in all incidence of CIPN (P<0.001), while no statistically significant differences in incidence of severe CIPN.There were statistically significant differences between GM1 group and thiamine tetrahydrofurfuryl disulphiele ( TTFD ) group in all incidence of CIPN and incidence of severe CIPN ( P<0.001).Conclusion GM1 is an effective neuroprotective agent against CIPN and did not affect the short -term efficacy of chemotherapy and is safety.In addition, GM1 has an advantage over GSH and TTFD in decreasing peripheral neurotoxicity by CIPN in cancer patients.
